PURE Completes Phase One Technology Transfer for Expanded Production -- Intercon SDC Facility Online
2014年1月23日 - 10:30PM
Marketwired
PURE Completes Phase One Technology Transfer for Expanded
Production -- Intercon SDC Facility Online
SAN DIEGO, CA--(Marketwired - Jan 23, 2014) - PURE Bioscience,
Inc. (OTCQB: PURE), creator of the patented silver dihydrogen
citrate (SDC) antimicrobial, today announced it has completed the
first phase of the SDC technology transfer to its collaboration
partner, Intercon Chemical Company (ICC). The first phase consists
of the partial transfer of PURE's unique and proprietary SDC
manufacturing process into a new and dedicated production facility
at ICC's St. Louis manufacturing location.
ICC invested in significant capital improvements to allow for
the new and dedicated SDC production capability. The Company stated
that the final phase of the SDC technology transfer into ICC's
facility is expected to be completed during the second calendar
quarter of 2014.
In December 2013, PURE and ICC established a strategic
collaboration agreement whereby:
- ICC licensed PURE's patents and technology know-how for the
exclusive manufacture for PURE of all current SDC-based products
and;
- ICC licensed the distribution rights for SDC-based products
into its core businesses of institutional cleaning and sanitation
products and is developing a new initiative focused on US hospital,
healthcare and medical facilities.
The strategic collaboration agreement is consistent with PURE's
business strategy:
- Laser focus on its go-to-market strategy in the food industry,
as a food safety solution.
- Outsource manufacturing and supply chain management to an
established company in order to lower operating costs and future
capital requirements while increasing capacity.
- License the distribution rights of its SDC-based products to
qualified and appropriate licensors for revenue generation in
non-core markets and earn royalty income.
Jim Epstein, President and CEO of ICC, stated, "Both our teams
have worked collaboratively and meticulously to design, build and
implement this new production capability to produce SDC-based
products for both our and PURE's customers. Given our established
FDA manufacturing capability, we believe our thirty years of
operating history, flexibility and reliability can deliver the
future SDC manufacturing requirements, no matter how large."
Hank Lambert, Chief Executive Officer of PURE Bioscience, added,
"The importance of the technology transfer is that it now enables
expanded SDC production capacity. This increased capacity is
integral to the support of our commercialization efforts as we
continue to see growing interest and acceptance from both food
processors and QSRs."
About Intercon Chemical Company Privately owned Intercon
Chemical Company in St. Louis, Missouri, employees more than 100
employees at its 250,000 square foot FDA and EPA-registered cGMP
compliant manufacturing facility. Intercon has operated for
more than 30 years in the cleaning and sanitation chemical
manufacturing and service industries with expertise in formulating,
manufacturing and marketing liquids, powders and solids as well as
packaging, labeling and customer training programs. Intercon
provides state-of-the-art chemical products and programs to its
network of distributors in multiple markets, including: food
service sanitation, healthcare and infection control, facility
management companies, janitorial supply companies, commercial floor
care, critical process cleaning, food processing facility
maintenance, institutional laundry, contract packaging and green
products. For more information about Intercon Chemical Company,
please visit www.interconchemical.com.
About PURE Bioscience, Inc. PURE Bioscience, Inc. is focused on
developing and commercializing its proprietary antimicrobial
products that provide solutions to the health and environmental
challenges of pathogen and hygienic control within the food
industry. The Company's technology platform is based on patented
stabilized ionic silver, and its initial products contain silver
dihydrogen citrate, or SDC. SDC is a broad-spectrum, non-toxic
antimicrobial agent, which offers 24-hour residual protection. As a
platform technology, SDC is distinguished from existing products in
the marketplace by its superior efficacy, reduced toxicity and the
inability of bacteria to form a resistance to it. PURE is
headquartered in El Cajon, California (San Diego metropolitan
area). Additional information on PURE is available at
www.purebio.com.
Forward-looking Statements Any statements contained in this
press release that do not describe historical facts may constitute
forward-looking statements as that term is defined in the Private
Securities Litigation Reform Act of 1995. Forward-looking
statements inherently involve risks and uncertainties that could
cause our actual results to differ materially from the
forward-looking statements. Factors that could cause or contribute
to such differences include, but are not limited to, the Company's
cash position and liquidity requirements, the Company's failure to
implement or otherwise achieve the benefits of its proposed
business initiatives and plans, acceptance of the Company's current
and future products and services in the marketplace, the ability of
the Company to develop effective new products and receive
regulatory approvals of such products, competitive factors,
dependence upon third-party vendors, including to manufacture its
products, and other risks detailed in the Company's periodic report
filings with the Securities and Exchange Commission,
including our annual report on Form 10-K filed October 24,
2013. You should not place undue reliance on these
forward-looking statements, which speak only as of the date of this
press release. By making these forward-looking statements, the
Company undertakes no obligation to update these statements for
revisions or changes after the date of this release.
Contacts: Tom Hemingway Redwood Investment Group 714-978-4425
Email Contact Terri MacInnis Director of IR Bibicoff + MacInnis,
Inc. 818-379-8500 Email Contact Company Contact: Peter C. Wulff CFO
& COO PURE Bioscience, Inc. 619-596-8600 ext.111 Email
Contact
PURE Bioscience (PK) (USOTC:PURE)
過去 株価チャート
から 6 2024 まで 7 2024
PURE Bioscience (PK) (USOTC:PURE)
過去 株価チャート
から 7 2023 まで 7 2024